Literature DB >> 22906263

Clinicopathological significance of mesothelin expression in invasive breast cancer.

L Wang1, Z Niu, L Zhang, X Liu, X Wang, F Li, Y Wang.   

Abstract

OBJECTIVES: This study evaluated the expression profile of the mesothelin (MSLN) gene and its prognostic significance in breast cancer.
METHODS: To evaluate the diagnostic and prognostic significance of mesothelin, immunohistochemistry was used to assess the level of mesothelin protein in surgically resected, formalin-fixed, paraffin-embedded invasive breast carcinoma specimens. Associations between mesothelin and other biomarkers, including oestrogen receptor (OR), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu), were also evaluated.
RESULTS: A total of 182 breast carcinoma specimens were included. Mesothelin protein was present in the membrane of malignant cells. There was correlation between the presence of mesothelin in tumour cells and tumour infiltration of the lymph node. There was no correlation between the presence of mesothelin and HER2/neu protein, OR and PR in tumour cells. Mesothelin levels were significantly associated with decreased overall survival.
CONCLUSIONS: Lymph node status, tumour size, HER2/neu and mesothelin protein levels in breast cancer cells were independent prognostic factors. Mesothelin could be useful as a prognostic marker of overall survival in invasive breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22906263     DOI: 10.1177/147323001204000309

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  9 in total

1.  Mesothelin expression and survival outcomes in triple receptor negative breast cancer.

Authors:  Napa Parinyanitikul; George R Blumenschein; Yun Wu; Xiudong Lei; Mariana Chavez-Macgregor; Melody Smart; Ana Maria Gonzalez-Angulo
Journal:  Clin Breast Cancer       Date:  2013-06-27       Impact factor: 3.225

2.  Mesothelin expression is associated with poor outcomes in breast cancer.

Authors:  Yun R Li; Rena R Xian; Amy Ziober; Jose Conejo-Garcia; Alfredo Perales-Puchalt; Carl H June; Paul J Zhang; Julia Tchou
Journal:  Breast Cancer Res Treat       Date:  2014-09-06       Impact factor: 4.872

3.  Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.

Authors:  Vincent Chen; Shigeki Umemura; Yumin Han; Renuka Raman; Robin Tucker; Joeffrey Chahine; In-Kyu Kim; Christoph Schatz; Sabine Zitzmann-Kolbe; Anette Sommer; Masanori Onda; Trevor Lee; Yongfeng He; Giuseppe Giaccone
Journal:  Br J Cancer       Date:  2021-12-07       Impact factor: 9.075

Review 4.  Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.

Authors:  Brendan L Hagerty; Guillaume J Pegna; Jian Xu; Chin-Hsien Tai; Christine Alewine
Journal:  Biomolecules       Date:  2020-06-28

5.  Lysosomal Biogenesis and Implications for Hydroxychloroquine Disposition.

Authors:  Keagan P Collins; Sandra Witta; Jonathan W Coy; Yi Pang; Daniel L Gustafson
Journal:  J Pharmacol Exp Ther       Date:  2020-11-10       Impact factor: 4.030

6.  ERC/mesothelin is expressed in human gastric cancer tissues and cell lines.

Authors:  Tomoaki Ito; Kazunori Kajino; Masaaki Abe; Koichi Sato; Hiroshi Maekawa; Mutsumi Sakurada; Hajime Orita; Ryo Wada; Yoshiaki Kajiyama; Okio Hino
Journal:  Oncol Rep       Date:  2013-10-22       Impact factor: 3.906

7.  Association between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: a protocol for a systematic review.

Authors:  Mei Wang; Aihua Li; Guangwen Sun; Lawrence Mbuagbaw; Susan Reid; Peter J Lovrics; Lehana Thabane
Journal:  Syst Rev       Date:  2016-08-11

8.  Overexpression of sulfatase-1 in murine hepatocarcinoma Hca-F cell line downregulates mesothelin and leads to reduction in lymphatic metastasis, both in vitro and in vivo.

Authors:  Salma Mahmoud; Mohammed Ibrahim; Ahmed Hago; Yuhong Huang; Yuanyi Wei; Jun Zhang; Qingqing Zhang; Yu Xiao; Jingwen Wang; Munkaila Adam; Yu Guo; Li Wang; Shuting Zhou; Boyi Xin; Wei Xuan; Jianwu Tang
Journal:  Oncotarget       Date:  2016-11-15

9.  Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal-type breast cancer.

Authors:  Takafumi Suzuki; Yoji Yamagishi; Takahiro Einama; Tomomi Koiwai; Tamio Yamasaki; Makiko Fukumura-Koga; Yusuke Ishibashi; Yasuhiro Takihata; Takehiro Shiraishi; Yoichi Miyata; Toshimitsu Iwasaki; Eiji Shinto; Kimiya Sato; Hideki Ueno; Junji Yamamoto; Yoji Kishi; Hitoshi Tsuda
Journal:  Oncol Lett       Date:  2020-09-03       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.